daraxonrasib
RMC-6236-301
Phase 3 small_molecule active
Quick answer
daraxonrasib for NSCLC (Non-small Cell Lung Cancer) is a Phase 3 program (small_molecule) at Revolution Medicines with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Revolution Medicines
- Indication
- NSCLC (Non-small Cell Lung Cancer)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active